Tumor-Infiltrating Lymphocyte Abundance Prognostic in Early-Stage TNBC
By Elana Gotkine HealthDay Reporter
THURSDAY, April 18, 2024 -- For patients with early-stage triple-negative breast cancer (TNBC) who undergo surgery without chemotherapy, tumor-infiltrating lymphocyte (TIL) abundance is associated with improved survival, according to a study published online April 2 in the Journal of the American Medical Association.
Roberto A. Leon-Ferre, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues examined the association of TIL abundance in breast cancer tissue with survival among patients with early-stage TNBC who were treated with locoregional therapy in a retrospective pooled analysis of individual patient-level data from 13 participating centers. A total of 1,966 participants diagnosed with TNBC between 1979 and 2017 who received treatment with surgery, with or without radiotherapy but without chemotherapy, were included.
The researchers found that the median TIL level was 15 percent, and 417 (21 percent) and 1,300 (66 percent) patients had a TIL ≥50 percent and <30 percent, respectively. For stage I TNBC, five-year survival free of distant recurrence (DRFS) was 94 and 78 percent for those with a TIL level of ≥50 versus <30 percent, respectively; corresponding five-year overall survival was 95 versus 82 percent. After adjustment for age, tumor size, nodal status, histological grade, and receipt of radiotherapy, at a median follow-up of 18 years, each 10 percent higher TIL increment was independently associated with improved invasive disease-free survival, recurrence-free survival, DRFS, and overall survival (hazard ratios, 0.92, 0.90, 0.87, and 0.88, respectively).
"These results suggest that breast tissue TIL abundance is a prognostic factor for patients with early-stage TNBC," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
2016 to 2021 Saw Increase in Number of Periprosthetic Fractures
TUESDAY, July 16, 2024 -- The number of periprosthetic fractures of the hip and knee increased in recent years and is projected to continue increasing, according to a study...
Some Women in Their 40s Prefer to Delay Breast Cancer Screening
MONDAY, July 15, 2024 -- A considerable proportion of women aged 39 to 49 years prefer to delay breast cancer screening, especially after a decision aid (DA) intervention...
Rates of Gender-Affirming Surgery Examined in Cisgender Males, Gender-Diverse
WEDNESDAY, July 10, 2024 -- For adults and minors, most breast reductions performed on cisgender males and transgender and gender-diverse (TGD) people are performed on cisgender...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.